Methods of treating at least one condition associated with envenomation, pharmaceutical compositions, and kits comprising a first compound having formula (I): and a second compound chosen from N-acetyl-L-cysteine, sodium aurothiomalate, silibinin, sodium copper chlorophyllin, and pharmaceutically acceptable salts and solvates thereof.

##STR00001##

The present invention relates to compositions containing a PIKfyve inhibitor, preferably apilimod, APY0201 or YM-201636, most preferably apilimod, for use in treating or preventing viral infections, preferably Ebola or Marburg virus infections. It also relates to a pharmaceutical pack or kit comprising apilimod and at least one additional anti-viral agent.

Immune cells engineered to reduce or eliminate expression and/or the function of a NR4A, TOX, NR4A and a TOX or NR4A and a TOX with increasing expression of IL-21 in said cells are disclosed. Also cells engineered to inhibit expression and/or function of NFAT/AP-1 pathway are provided. Disclosed cells are T and NK cells. It can be expanded to create homogeneous or heterogenous cell populations and/or combined with pharmaceutically acceptable carriers. It can be CAR cells. Methods to induce an immune response and treat conditions requiring selective immunotherapy, comprising contacting a target cell with the cells or compositions as described herein. The contacting can be performed in vitro or in vivo, thereby providing immunotherapy to a subject. Additionally presented herein are methods of producing such engineered cells. Kits containing the materials for making and using the cells are also provided.

The present invention relates to compositions containing a PIKfyve inhibitor, preferably apilimod, APY0201 or YM-201636, most preferably apilimod, for use in treating or preventing viral infections, preferably Ebola or Marburg virus infections. It also relates to a pharmaceutical pack or kit comprising apillimod and at least one additional anti-viral agent.

This invention is directed to vaccine compositions and methods of using the same to prevent infection.

Described herein are multi-specific binding agents that bind A33 and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Also provided herein are methods of using multi-specific binding agents or compositions thereof for the detection, prevention, and/or therapeutic treatment of diseases characterized by expression of the A33 glycoprotein antigen, in particular, colorectal cancer.

Chimeric double peptide vaccines are disclosed, useful for inducing active immunity against Candida fungal infections. The chimeric peptide comprises an Fba peptide and an Met6 peptide, covalently linked to one another, with or without an intermediate linker. Fba and Met6 are cell surface components of Candida. When used as a vaccine, the chimeric double peptide vaccine induces stronger protective immunity against fungal infection than does the Fba peptide alone, or the Met6 peptide alone, or a mixture (not covalently linked) of the two peptides.

The invention provides compositions and methods for preventing or reducing the severity of malaria.

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., skin cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody). In certain embodiments, the skin cancer is cutaneous squamous cell carcinoma or basal cell carcinoma.

The present invention features compositions comprising an anti-amyloid antibody and methods of treating microbial infection and treating or preventing microbial biofilms using the composition.